research use only

Ciclopirox ATPase inhibitor

Name: Ciclopirox
Brand: Selleck Chemicals
SKU: S2528
Availability: InStock
Rating: 5 (5 reviews)

Cat.No.S2528

Ciclopirox (HOE 296b, Penlac) is a broad-spectrum antifungal agent working as an iron chelator. This compound is a broad-spectrum antifungal agent working as an iron chelator. This chemical is a broad-spectrum antifungal agent working as an iron chelator.

Chemical Structure

Molecular Weight: 207.27

Jump to

Quality Control

Batch: S252801 DMSO]41 mg/mL]false]Ethanol]41 mg/mL]false]Water]Insoluble]false Purity: 99.88%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS/MSDS
Datasheet

99.88

Related Targets	CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel GluR
Other ATPase Inhibitors	(-)-Blebbistatin Thapsigargin Brefeldin A (BFA chemical) CB-5083 Golgicide A Sodium orthovanadate Bufalin CDN1163 Ginsenoside Rb1 Oligomycin

Solubility

In vitro
Batch:

DMSO : 41 mg/mL (197.8 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 41 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.000mg/ml (14.47mM)	Taking the 1 mL working solution as an example, add 50 μL of 60 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	207.27	Formula	C₁₂H₁₇NO₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	29342-05-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	HOE 296b, Penlac			SMILES	CC1=CC(=O)N(C(=C1)C2CCCCC2)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	ATPase
In vitro	Ciclopirox olamine (CPX) is a lipophilic bidentate iron chelator that stabilizes HIF-1alpha under normoxic conditions at lower concentrations than other iron chelators, probably by inhibiting HIF-1alpha hydroxylation. This compound-induced HIF-1 mediates reporter gene activity and endogenous HIF-1 target gene expression, including elevation of transcription, mRNA, and protein levels of the vascular endothelial growth factor (VEGF). It inhibits growth of C. albicans yeast and hyphal cells in a dose-dependent manner. This chemical blocks H2O2-induced mitochondrial injury by maintaining mitochondrial transmembrane potential (Deltapsim). It completely blocks H2O2-stimulated release of lactate dehydrogenase (a marker of cell death) and decreases in MTT reduction (a marker of mitochondrial function) in adenocarcinoma SK-HEP-1 cells. This compound effectively inhibits H2O2-induced mitochondrial permeability transition pore (MPTP) opening. It increases the MTP, maintained it high, and blocks the ATP depletion in glucose-deprived SIN-1-treated astrocytes. This chemical protects astrocytes from peroxynitritecytotoxicity by attenuating peroxynitrite-induced mitochondrial dysfunction. It is a substituted pyridone antimycotic drug, unrelated to the imidazole derivatives and its topical application ensures maximum local bioavailability. This compound acts on fungi by inhibiting the intracellular uptake of essential substrates and ions and this probably acts on the Candida ability to express its adherence mechanisms.
References	[1] https://pubmed.ncbi.nlm.nih.gov/12594177/ [2] https://pubmed.ncbi.nlm.nih.gov/15790671/ [3] https://pubmed.ncbi.nlm.nih.gov/15806112/ [4] https://pubmed.ncbi.nlm.nih.gov/12243770/ [5] https://pubmed.ncbi.nlm.nih.gov/1492854/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-03-24)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07024316	RECRUITING	Congenital Erythropoietic Porphyria (CEP)	Atlas Molecular Pharma	2026-01-29	PHASE1; PHASE2
NCT05647343	COMPLETED	Adverse Effect of Drugs and Medicaments in Therapeutic Use	Atlas Molecular Pharma	2023-03-31	PHASE1
NCT05809297	UNKNOWN	Onychomycosis	Universidad Complutense de Madrid	2023-09-01	PHASE4
NCT02866032	COMPLETED	Distal Subungual Onychomycosis	Moberg Pharma AB	2016-09	PHASE3
NCT02961634	UNKNOWN	Onychomycosis	MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA	2017-04	PHASE3
NCT02679911	COMPLETED	Foot Dermatoses	Galderma R&D	2015-09	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):